会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • BIOADHESIVE POLYMERS WITH CATECHOL FUNCTIONALITY
    • 具有CATECHOL功能的生物聚合物
    • WO2005056708A2
    • 2005-06-23
    • PCT/US2004/041783
    • 2004-12-09
    • SPHERICS, INC.SCHESTOPOL, Marcus, A.JACOB, Jules, S.DONNELY, RyanRICKETTS, Thomas, L.NANGIA, AvinashMATHIOWITZ, EdithSHAKED, Ze'ev
    • SCHESTOPOL, Marcus, A.JACOB, Jules, S.DONNELY, RyanRICKETTS, Thomas, L.NANGIA, AvinashMATHIOWITZ, EdithSHAKED, Ze'ev
    • C09J129/00
    • C08F8/32A61K9/0004A61K9/006A61K9/0065A61K9/204A61K9/2077A61K9/2081A61K9/2086C08G63/91C08G63/912C09J167/00C09J167/04C08F222/06
    • Polymers with improved bioadhesive properties and methods for improving bioadhesion of polymers have been developed. A compound containing an aromatic group which contains one or more hydroxyl groups is grafted onto a polymer or coupled to individual monomers. In one embodiment, the polymer is a biodegradable polymer. In another embodiment, the monomers may be polymerized to form any type of polymer, including biodegradable and non-biodegradable polymers. In some embodiments, the polymer is a hydrophobic polymer. In the preferred embodiment, the polymer is a hydrophobic polymer. In the preferred embodiment, the aromatic compound is catechol or a derivative thereof and the polymer contains reactive functional groups. In the most preferred embodiment, the polymer is a polyanhydride and the aromatic compound is the catechol derivative, DOPA. These materials display bioadhesive properties superior to conventional bioadhesives used in therapeutic and diagnostic applications. These bioadhesive materials can be used to fabricate new drug delivery or diagnostic systems with increased residence time at tissue surfaces, and consequently increase the bioavailability of a drug or a diagnostic agent. In a preferred embodiment, the bioadhesive material is a coating on a controlled release oral dosage formulation and/or forms a matrix in an oral dosage formulation.
    • 已经开发了具有改进的生物粘附性质的聚合物和改善聚合物生物粘附的方法。 含有含有一个或多个羟基的芳族基团的化合物被接枝到聚合物上或与单独的单体偶联。 在一个实施方案中,聚合物是可生物降解的聚合物。 在另一个实施方案中,单体可以聚合以形成任何类型的聚合物,包括可生物降解和不可生物降解的聚合物。 在一些实施方案中,聚合物是疏水性聚合物。 在优选的实施方案中,聚合物是疏水性聚合物。 在优选的实施方案中,芳族化合物是儿茶酚或其衍生物,并且聚合物含有反应性官能团。 在最优选的实施方案中,聚合物是聚酐,芳族化合物是邻苯二酚衍生物DOPA。 这些材料显示出比用于治疗和诊断应用的常规生物粘合剂优越的生物粘附性。 这些生物粘附材料可用于制造具有增加的组织表面停留时间的新药物递送或诊断系统,并因此提高药物或诊断剂的生物利用度。 在优选的实施方案中,生物粘附材料是在控释口服剂量制剂上的涂层和/或在口服剂量制剂中形成基质。
    • 4. 发明申请
    • BIOADHESIVE POLYMERS WITH CATECHOL FUNCTIONALITY
    • 具有儿茶酚官能度的亲水聚合物
    • WO2005056708A3
    • 2005-07-28
    • PCT/US2004041783
    • 2004-12-09
    • SPHERICS INCSCHESTOPOL MARCUS AJACOB JULES SDONNELY RYANRICKETTS THOMAS LNANGIA AVINASHMATHIOWITZ EDITHSHAKED ZE EV
    • SCHESTOPOL MARCUS AJACOB JULES SDONNELY RYANRICKETTS THOMAS LNANGIA AVINASHMATHIOWITZ EDITHSHAKED ZE EV
    • A61K9/00A61K9/20A61K31/74C08F8/32C08G63/91C09J135/00C09J167/00C09J167/04C09J201/06C08F222/06C08G67/04
    • C08F8/32A61K9/0004A61K9/006A61K9/0065A61K9/204A61K9/2077A61K9/2081A61K9/2086C08G63/91C08G63/912C09J167/00C09J167/04C08F222/06
    • Polymers with improved bioadhesive properties and methods for improving bioadhesion of polymers have been developed. A compound containing an aromatic group which contains one or more hydroxyl groups is grafted onto a polymer or coupled to individual monomers. In one embodiment, the polymer is a biodegradable polymer. In another embodiment, the monomers may be polymerized to form any type of polymer, including biodegradable and non-biodegradable polymers. In some embodiments, the polymer is a hydrophobic polymer. In the preferred embodiment, the polymer is a hydrophobic polymer. In the preferred embodiment, the aromatic compound is catechol or a derivative thereof and the polymer contains reactive functional groups. In the most preferred embodiment, the polymer is a polyanhydride and the aromatic compound is the catechol derivative, DOPA. These materials display bioadhesive properties superior to conventional bioadhesives used in therapeutic and diagnostic applications. These bioadhesive materials can be used to fabricate new drug delivery or diagnostic systems with increased residence time at tissue surfaces, and consequently increase the bioavailability of a drug or a diagnostic agent. In a preferred embodiment, the bioadhesive material is a coating on a controlled release oral dosage formulation and/or forms a matrix in an oral dosage formulation.
    • 已经开发出具有改善的生物粘附性质的聚合物和用于改善聚合物的生物粘附性的方法。 含有含一个或多个羟基的芳族基团的化合物接枝到聚合物上或与单独的单体偶联。 在一个实施方案中,聚合物是可生物降解的聚合物。 在另一个实施方案中,单体可以聚合形成任何类型的聚合物,包括可生物降解和不可生物降解的聚合物。 在一些实施例中,聚合物是疏水性聚合物。 在优选的实施方案中,聚合物是疏水性聚合物。 在优选的实施方案中,芳族化合物是儿茶酚或其衍生物,聚合物含有反应性官能团。 在最优选的实施方案中,聚合物是聚酐,芳族化合物是邻苯二酚衍生物DOPA。 这些材料的生物粘附性能优于用于治疗和诊断应用的常规生物粘附剂。 这些生物粘附材料可用于制造在组织表面处具有增加的停留时间的新型药物递送或诊断系统,并因此增加药物或诊断剂的生物利用度。 在一个优选的实施方案中,生物粘附材料是控释口服剂型中的包衣和/或在口服剂型中形成基质。